title: [Bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration: a case report].
abstract: The antiangiogenic drugs have been recently introduced in the therapeutic armamentarium of choroidal neovascularization. The purpose of this report is to describe a case of occult choroidal neovascularization with extensive retinal pigment epithelial detachment treated with intravitreal bevacizumab (Avastin). The efficacy of the medication was evaluated by means of visual acuity and complementary exams (fluorescein angiography, indocyanine green video angiography and optical coherence tomography). After three intravitreal injections of bevacizumab a satisfactory anatomic and visual response was achieved, showing benefits of the drug, despite the extensive retinal pigment epithelial detachment associated with occult choroidal neovascularization.
authors.affiliation: Departamento de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil. t_arantes@yahoo.com
authors.forename: Tiago Eugênio Faria e
authors.initials: TE
authors.lastname: Arantes
authors.forename: Vinícius Paganini
authors.initials: VP
authors.lastname: Nascimento
authors.forename: Otacílio de Oliveira
authors.initials: OO
authors.lastname: Maia
authors.forename: Walter Yukihiko
authors.initials: WY
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008268:Macular Degeneration / Q000150:complications*; D012163:Retinal Detachment / Q000175:diagnosis / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab